Summary
Pre-clinical animal models of spontaneous metastatic cancer are infrequent; the few that exist are resource intensive because determination of the presence of metastatic disease, metastatic burden, and response to therapy normally require multiple timed cohorts with animal sacrifice and extensive pathological examination. We identified and characterized a patient derived xenograft model with metastatic potential, adenocarcinoma pancreas xenograft 521955-158-R4. In this study we performed a detailed imaging characterization (workflow below) of this model, which develops spontaneous lung metastases, details are provided in the attached standard operating procedures. Tumors in half of the mice were resected in the range 200-300 cm3 size; tumors in the other half were allowed to grow until it was necessary to euthanize them because of tumor size.The imaging characteristics of this model (PDMR-521955-158-R4), which is available from the National Cancer Institute Patient-Derived Models Repository (https://pdmr.cancer.gov/), is highly favorable for preclinical research studies of metastatic disease when used in conjunction with non-contrast T2 weighted MRI.
Results: Adenocarcinoma pancreas (PDMR-521955-158-R4)
Table 1: Penetrance and location of pathological confirmed metastatic lesion(s).
# animals in Group | # animals that displayed metastasis in MRI and confirmed by Pathology | Pathology confirmation of MRI (primary imaging site) | Other confirmed Location (s) | Mouse ID: MRI with pathology confirmation of metastasis |
10 (non-resected) | 4 (5 mice were EU due to xenograft size prior to observation of metastases) | Lung | Lung | 2163, 2169, 2171, 2179 |
10 (resected) | 7 | Lung | Lung (70%) Para-vertebral muscle (50%) Nodal disease (10%) | 2160, 2161, 2164, 2170, 2172, 2176, 2178 |
Percent penetrance with respect to the average time-to-metastasis for non-resected (time from implant: 10.7 ± 1.8 weeks) and resected (time from tumor resection: 5.3 ± 1.1 weeks) cohorts.
PET/CT Characterization of the primary tumor: Baseline PET (SOP attached) were performed when tumor reached an approximate 200 mm3. Average SUVmax values (n=6) were calculated; [18F]FDG: 2.3 ± 0.8 and [18F]FLT: 2.4 ± 0.4.
Conclusion:
Good metastatic model with 40% penetrance un-resected and 70% with planned early resection. Metastases are well observed on T2 MRI imaging allowing non-invasive evaluation in treatment trials.
Acknowledgements
We would like to acknowledge the individuals and institutions that have provided data for this collection:
Frederick National Laboratory for Cancer Research – Special Thanks to Joseph D. Kalen, PhD, Lilia V. Ileva, MS, Lisa A Riffle, Nimit Patel, Keita Saito, PhD, Yvonne Evrard, PhD, Elijah Edmondson, DVM, PhD, Justin Smith, Simone Difilippantonio, PhD, Chelsea Sanders, Ulrike Wagner, Yanling Liu, PhD, John B. Freymann, and Justin Kirby.
Division of Cancer Therapeutics and Diagnosis/National Cancer Institute - James L. Tatum, MD, Paula M Jacobs, PhD, Melinda G. Hollingshead, DVM, and James H. Doroshow, MD
PixelMed Publishing – Special Thanks to David A. Clunie, MD
University of Arkansas for Medical Sciences – Special Thanks to Kirk E. Smith
Data Access
| Data Type | Download all or Query/Filter | License |
|---|---|---|
Images (DICOM, XX.X GB) | (Download requires NBIA Data Retriever) | |
| PDMR Patient Specimen (external) | (Download requires Aspera plugin) | |
| Standard Operating Procedure 50101: MRI T2 Weighted Non-Contrast Protocol: Single Mouse Pulmonary Gated and Multi-Mouse Non-Gated | ||
Standard Operating Procedure 50102: Positron Emission Tomography (PET) imaging protocol |
Click the Versions tab for more info about data releases.
Detailed Description
Image Statistics | Radiology Image Statistics | Pathology Image Statistics |
|---|---|---|
Modalities | MR | |
Number of Patients | 20 | |
Number of Studies | ||
Number of Series | ||
Number of Images | ||
| Images Size (GB) |
Citations & Data Usage Policy
Users must abide by the TCIA Data Usage Policy and Restrictions. Attribution should include references to the following citations:
Data Citation
DOI goes here. Create using Datacite with information from Collection Approval form
Publication Citation
We ask on the proposal form if they have ONE traditional publication they'd like users to cite.
Acknowledgement
This project has been funded in whole or in part with Federal funds from the National Cancer Institution, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
TCIA Citation
Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, Moore S, Phillips S, Maffitt D, Pringle M, Tarbox L, Prior F. The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository, Journal of Digital Imaging, Volume 26, Number 6, December, 2013, pp 1045-1057. DOI: 10.1007/s10278-013-9622-7
Other Publications Using This Data
TCIA maintains a list of publications which leverage TCIA data. If you have a manuscript you'd like to add please contact the TCIA Helpdesk.
Version X (Current): Updated yyyy/mm/dd
| Data Type | Download all or Query/Filter | License |
|---|---|---|
Image (DICOM, XX.X GB) | (Download requires the NBIA Data Retriever) | |
| PDMR Patient Specimen (external) | ||
| Standard Operating Procedure 50101: MRI T2 Weighted Non-Contrast Protocol: Single Mouse Pulmonary Gated and Multi-Mouse Non-Gated | ||
Standard Operating Procedure 50102: Positron Emission Tomography (PET) imaging protocol |
<< One or two sentences about what you changed since last version. No note required for version 1. >>